Eterna Therapeutics INC S-1 registration statements

Preclinical-stage biotech Ernexa Therapeutics Inc. is offering up to 13.59 million shares and accompanying warrants to raise an estimated $11.5 million for product development and working capital.

Ernexa Therapeutics Inc., a preclinical-stage cell therapy company, is offering up to $12.5 million in common stock and warrants to fund operations, despite significant accumulated losses and substantial doubt about its ability to continue as a going concern.

Eterna Therapeutics has filed a registration statement for the potential resale of up to 49,870,566 shares of its common stock by selling stockholders.